Donald D. Rao

Gradalis (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

17h-index1.7kcitations28works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA Interference and Gene Delivery(16), Advanced biosensing and bioanalysis techniques(11), MicroRNA in disease regulation(6), Virus-based gene therapy research(5), RNA modifications and cancer(5)

Publications28 total

Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden–High Ovarian Cancer
JCO Precision Oncology·2026Open Access
KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex
PLoS ONE·2018· 13 citedOpen Access
Assessment of Low Dose Vigil® Engineered Autologous Tumor Cell (EATC) Immunotherapy in Patients with Advanced Solid Tumors
Clinics in Oncology·2017· 3 cited
Preclinical Biodistribution and Safety Evaluation of a pbi-shRNA STMN1 Lipoplex after Subcutaneous Delivery
Toxicological Sciences·2016· 10 citedOpen Access
Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma
Molecular Therapy·2016· 42 citedOpen Access
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer
Molecular Therapy·2015· 20 citedOpen Access
Assessment of intravenous pbi-shRNA PDX1 nanoparticle (OFHIRNA-PDX1) in yucatan swine
Cancer Gene Therapy·2013· 8 citedOpen Access
RNA interference and personalized cancer therapy.
PubMed·2013· 27 cited
Bifunctional Short Hairpin RNA (bi-shRNA): Design and Pathway to Clinical Application
Methods in molecular biology·2012· 17 cited
PDX-1 Is a Therapeutic Target for Pancreatic Cancer, Insulinoma and Islet Neoplasia Using a Novel RNA Interference Platform
PLoS ONE·2012· 27 citedOpen Access
Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer
Molecular Therapy·2011· 193 citedOpen Access
RNA Interference and Cancer Therapy
Pharmaceutical Research·2011· 165 cited
<i>In vivo</i> Safety and Antitumor Efficacy of Bifunctional Small Hairpin RNAs Specific for the Human Stathmin 1 Oncoprotein
DNA and Cell Biology·2011· 40 cited
Personalized Cancer Approach: Using RNA Interference Technology
World Journal of Surgery·2011· 8 cited
Potential use of RNA interference in cancer therapy
Expert Reviews in Molecular Medicine·2010· 51 cited
Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference
Cancer Gene Therapy·2010· 47 cited
siRNA Versus shRNA for Personalized Cancer Therapy: Mechanisms and Applications
2010
Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development
Cancer Gene Therapy·2009· 92 cited
siRNA vs. shRNA: Similarities and differences
Advanced Drug Delivery Reviews·2009· 636 cited
1023. New Generation of shRNA for Targeted Cancer Gene Therapy
Molecular Therapy·2006Open Access
page 1 of 2Next →

Frequent Co-authors

John Nemunaitis(20), Neil Senzer(16), Padmasini Kumar(9), Zhaohui Wang(8), Chris Jay(5), Alice Huang(5), F. Charles Brunicardi(5), Beena O. Pappen(4), Phillip B. Maples(4), Christopher M. Jay(4), Minal Barve(3), Connor Phalon(3), Xiuquan Luo(3), John S. Vorhies(2), Joseph A. Kuhn(2), Jonathan Oh(2), Cynthia Bedell(2), Yang Yu(2), Nicolas Taquet(2), F. Charles Brunicardi(2)